ZMC(SH:600216)2020-10-22 16:00Financial Performance - Net profit attributable to shareholders increased by 72.30% to CNY 620,534,300.81 for the first nine months of the year[18]. - The net profit after deducting non-recurring gains and losses increased by 92.27% to CNY 555,064,145.95 for the first nine months of the year[18]. - Basic earnings per share rose by 71.05% to CNY 0.65[18]. - The company's net profit margin is not explicitly stated, but the decrease in retained earnings to ¥4,042,099,688.04 from ¥4,379,865,887.23 suggests a potential decline in profitability[46]. - Net profit for Q3 2020 was ¥182,764,138.01, compared to ¥74,089,027.54 in Q3 2019, representing a significant increase of 146.00%[54]. - The total profit for Q3 2020 was CNY 140,811,052.12, an increase of 8.5% from CNY 129,514,724.99 in Q3 2019[62]. Revenue and Costs - Total operating revenue for Q3 2020 reached ¥1,901,055,600.47, an increase of 9.67% compared to ¥1,733,802,914.79 in Q3 2019[50]. - Total operating costs for Q3 2020 were ¥1,696,882,687.41, up from ¥1,653,919,883.16 in Q3 2019, reflecting a rise of 2.00%[50]. - The gross profit margin for Q3 2020 was approximately 16.00%, compared to 10.00% in Q3 2019, indicating improved profitability[54]. - The gross profit margin for Q3 2020 was approximately 61.0%, compared to 57.3% in Q3 2019[59]. Assets and Liabilities - Total assets increased by 4.05% to CNY 10,782,338,812.63 compared to the end of the previous year[18]. - The total assets increased to CNY 10,782,338,812.63 from CNY 10,362,361,270.54, indicating a growth in the company's asset base[39]. - The company's total liabilities increased to CNY 2,355,339,906.71 from CNY 2,050,577,560.29, indicating a rise in financial obligations[39]. - Total liabilities reached ¥2,898,374,019.25, up from ¥2,110,157,955.49, indicating a significant increase of approximately 37.24%[46]. - The company's long-term borrowings increased to CNY 500,587,200.00, reflecting a rise in long-term bank loans[27]. - Total liabilities amounted to approximately ¥2,110,157,955.49, with current liabilities totaling ¥2,050,577,560.29[80]. Cash Flow - Operating cash flow increased by 119.72% to CNY 745,121,054.12 for the first nine months of the year[18]. - The cash flow from operating activities for the first three quarters of 2020 was CNY 5,641,252,469.38, slightly down from CNY 5,687,354,514.27 in the same period of 2019[64]. - The net cash flow from operating activities for the first three quarters of 2020 was ¥917,420,337.15, an increase from ¥586,100,980.11 in the same period of 2019, representing a growth of approximately 56.5%[71]. - The total cash inflow from investment activities was ¥751,993,138.40, compared to ¥516,753,330.92 in the previous year, indicating a year-over-year increase of about 45.5%[73]. - The net cash flow from financing activities was -¥94,236,086.90, a decline from -¥10,670,272.85 in the same period last year, reflecting a worsening cash position in financing[73]. Research and Development - The company's R&D expenses increased by 67.70% to CNY 395,225,544.71 compared to CNY 235,679,432.25 in the same period last year, reflecting a significant increase in investment in research and development[27]. - Research and development expenses in Q3 2020 amounted to ¥184,475,797.76, a substantial increase of 47.94% from ¥124,627,405.74 in Q3 2019[50]. - Research and development expenses increased to CNY 130,182,821.69 in Q3 2020, a rise of 20.5% from CNY 108,030,744.92 in Q3 2019[59]. Investment Income - Investment income rose by 185.27% to CNY 110,107,312.68 from CNY 38,597,467.13, primarily due to increased returns from trust and financial products, as well as gains from the sale of part of the shares in Xianju Pharmaceutical[27]. - The total investment income for Q3 2020 was ¥8,805,203.84, up from ¥6,122,575.48 in Q3 2019, indicating a growth of 43.93%[54]. - The investment income for Q3 2020 showed a loss of CNY 69,688,543.53, compared to a minimal loss of CNY 3,822.27 in Q3 2019[60]. Future Outlook - The company expects a significant increase in cumulative net profit compared to the same period last year due to substantial price increases in its main products, Vitamin E and Vitamin A, since March 2020[30]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[60].